Suppr超能文献

冠状病毒感染的免疫反应:是敌是友?

The Immune Responses against Coronavirus Infections: Friend or Foe?

机构信息

Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.

Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.

出版信息

Int Arch Allergy Immunol. 2021;182(9):863-876. doi: 10.1159/000516038. Epub 2021 May 5.

Abstract

Coronaviruses (CoVs) were first discovered in the 1960s. Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) has been identified as the cause of COVID-19, which spread throughout China and subsequently, across the world. As COVID-19 causes serious public health concerns across the world, investigating the characteristics of SARS-CoV-2 and its interaction with the host immune responses may provide a clearer picture of how the pathogen causes disease in some individuals. Interestingly, SARS-CoV-2 has 80% sequence homology with SARS-CoV-1 and 96-98% homology with CoVs isolated from bats. Therefore, the experience acquired in SARS and Middle East Respiratory Syndrome (MERS) epidemics may improve our understanding of the immune response and immunopathological changes in COVID-19 patients. In the present paper, we have reviewed the immune responses (including the innate and adaptive immunities) to SARS-CoV, MERS-CoV, and SARS-CoV-2, so as to improve our understanding of the concept of the COVID-19 disease, which will be helpful in developing vaccines and medications for treating the COVID-19 patients.

摘要

冠状病毒(CoVs)于 20 世纪 60 年代首次被发现。严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)已被确定为 COVID-19 的病因,该病毒在中国各地传播,随后在全球范围内传播。由于 COVID-19 在全球范围内引起严重的公共卫生关注,因此研究 SARS-CoV-2 的特征及其与宿主免疫反应的相互作用可能会更清楚地了解病原体如何在某些个体中引起疾病。有趣的是,SARS-CoV-2 与 SARS-CoV-1 具有 80%的序列同源性,与蝙蝠中分离出的冠状病毒具有 96-98%的同源性。因此,在 SARS 和中东呼吸综合征(MERS)流行期间获得的经验可能会增进我们对 COVID-19 患者免疫反应和免疫病理变化的理解。在本文中,我们回顾了对 SARS-CoV、MERS-CoV 和 SARS-CoV-2 的免疫反应(包括先天免疫和适应性免疫),以便更好地理解 COVID-19 疾病的概念,这将有助于为 COVID-19 患者开发疫苗和药物。

相似文献

1
The Immune Responses against Coronavirus Infections: Friend or Foe?冠状病毒感染的免疫反应:是敌是友?
Int Arch Allergy Immunol. 2021;182(9):863-876. doi: 10.1159/000516038. Epub 2021 May 5.
3
Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.新型冠状病毒病与其他冠状病毒病的异同。
Annu Rev Microbiol. 2021 Oct 8;75:19-47. doi: 10.1146/annurev-micro-110520-023212. Epub 2021 Jan 25.
10
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.2020 年大流行:当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.

引用本文的文献

6
COVID-19 diagnostics: Molecular biology to nanomaterials.COVID-19 诊断学:从分子生物学到纳米材料。
Clin Chim Acta. 2023 Jan 1;538:139-156. doi: 10.1016/j.cca.2022.11.017. Epub 2022 Nov 18.

本文引用的文献

2
Maintaining Safety with SARS-CoV-2 Vaccines.通过新冠病毒疫苗维持安全性。
N Engl J Med. 2021 Feb 18;384(7):643-649. doi: 10.1056/NEJMra2035343. Epub 2020 Dec 30.
4
8
Immunological considerations for COVID-19 vaccine strategies.针对 COVID-19 疫苗策略的免疫学考虑。
Nat Rev Immunol. 2020 Oct;20(10):615-632. doi: 10.1038/s41577-020-00434-6. Epub 2020 Sep 4.
10
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗:全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验